Celera, Applied Biosystems go separate ways
This article was originally published in Clinica
Executive Summary
Diagnostic tests and services provider Celera has officially become an independent company, after its separation from parent company Applera was completed Tuesday (July 1). Celera was founded by Applera in 1998 with the mission of sequencing the human genome – since then, its business has grown significantly in the genetic diagnostics and personalised disease management field, particularly through the recent acquisitions of Berkeley HeartLab and Atria Genetics. Celera is now trading under the symbol "CRA". As a result of the separation, Applera has taken on the name of its remaining life science equipment business, Applied Biosystems. In June, the latter agreed to a merger with Invitrogen, in a deal worth $6.9bn (see Clinica No 1311, p 2).